Evidence map›Paper›PMID 27920708›Full record

ArticleCase reports in oncology

Cutaneous Metastasis due to Breast Cancer in a Patient with Primary Biliary Cirrhosis: A Case Report.

Sailaja Kamaraju, Jill Depke, Janice Povletich, Adam Currey, Elizabeth Weil

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sailaja KamarajuDepartment of Internal Medicine, Department of Clinical Nursing, Department of Radiation Oncology, and Department of Pharmacy, Froedtert/Medical College of Wisconsin, Milwaukee, WI, USA.
Jill DepkeDepartment of Internal Medicine, Department of Clinical Nursing, Department of Radiation Oncology, and Department of Pharmacy, Froedtert/Medical College of Wisconsin, Milwaukee, WI, USA.
Janice PovletichDepartment of Internal Medicine, Department of Clinical Nursing, Department of Radiation Oncology, and Department of Pharmacy, Froedtert/Medical College of Wisconsin, Milwaukee, WI, USA.
Adam CurreyDepartment of Internal Medicine, Department of Clinical Nursing, Department of Radiation Oncology, and Department of Pharmacy, Froedtert/Medical College of Wisconsin, Milwaukee, WI, USA.
Elizabeth WeilDepartment of Internal Medicine, Department of Clinical Nursing, Department of Radiation Oncology, and Department of Pharmacy, Froedtert/Medical College of Wisconsin, Milwaukee, WI, USA.
Medical College of Wisconsin · USFroedtert Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is the most common solid tumor to cause cutaneous metastases. These are incurable and the treatment goal is geared toward local control with surgical excision, radiation, and chemotherapy. However, treatment can be challenging in subjects with end-stage liver disease and a multidisciplinary approach is warranted. CASE REPORT: In this case report, we present a 61-year-old female with primary biliary cirrhosis and human epidermal growth factor-2 (HER-2)-positive breast cancer, who subsequently developed cutaneous metastases. We briefly describe the treatment challenges due to underlying end-stage liver disease, and an exceptional response to trastuzumab and nab-paclitaxel.

conclusionA multidisciplinary approach to local control and attenuated doses of nab-paclitaxel and trastuzumab suggest a durable response to HER-2-positive breast cancer with cutaneous metastasis. Subjects with end-stage liver disease pose unique challenges and toxicities, warranting additional research and drug development for less hepatotoxic antineoplastic agents.

Indexed as

Cutaneous metastasisHER-2-positive breast cancerNab-paclitaxelPrimary biliary cirrhosis

Identifiers

PMID27920708
PMCPMC5126598
OpenAlexW2554511801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.